Eli Lilly’s Innovation Statement: Advocating Drug Pricing Reforms

By HEOR Staff Writer

August 18, 2025

Eli Lilly has issued a statement advocating for US drug pricing reforms. It emphasizes maintaining America’s leadership in biopharmaceutical innovation. The Eli Lilly innovation statement highlights a $50 billion US manufacturing investment since 2020. This includes four new sites and opposes tariffs that could disrupt access and raise costs. Lilly stresses balancing affordability with financial viability for R&D.

Key Insights

Investment in Domestic Manufacturing: Lilly’s $50 billion expansion is among the largest recent US pharmaceutical investments. It aims to boost API production and injectable therapy capacity while creating high-skilled jobs.

Strategic Position on Pricing: The company supports a nuanced pricing approach. It warns that US price cuts must sustain innovation funding, possibly requiring adjustments in other markets.

Opposition to Trade Barriers: Lilly opposes pharmaceutical tariffs, arguing they increase costs and harm patient access. Such measures could weaken US competitiveness in drug development.

Partnership Approach: The company advocates for public-private partnerships. It calls for incentives like tax credits to balance innovation with patient access.

Background Context

The US pharmaceutical market has higher drug prices than other nations. This has drawn criticism but also funds global R&D. Drug pricing reform debates have grown, with policies aiming to balance affordability and innovation. Manufacturing reshoring has gained importance post-COVID for supply chain resilience.

Implications

Health Economics Impact: Lilly’s stance highlights global market ties and innovation financing. US price cuts may lead to hikes elsewhere.

Manufacturing Strategy: The $50 billion investment boosts domestic production, improving supply chain resilience for critical medications.

Policy Considerations: The company prefers targeted incentives over tariffs, urging nuanced healthcare industrial policies.

Innovation Sustainability: Balancing affordability with R&D funding remains key for long-term innovation and patient access.

For details, see the Eli Lilly innovation statement here.

Reference url

Recent Posts

Vitamin B6 Depletion Risk in Carbidopa/Levodopa Therapy and Seizure Implications

By HEOR Staff Writer

March 25, 2026

Carbidopa/levodopa products used for Parkinson’s disease can cause vitamin B6 depletion risk, potentially leading to seizures. The U.S. Food and Drug Administration (FDA) has identified 14 cases of seizures linked to vitamin B6 deficiency, all occurring in patients taking levodopa doses above 1,0...
Citation Analysis of Real-World Evidence in Medicare Drug Price Negotiations

By João L. Carapinha

March 24, 2026

Medicare Drug Price Negotiations are increasingly relying on real-world evidence, according to a new citation analysis of the first drugs selected under the Inflation Reduction Act. The study examined how the Centers for Medicare and Medicaid Services (CMS) uses real-world evidence (RWE) in its M...
Serplulimab Lung Cancer Treatment: Evaluation of Clinical and Economic Impact in Portugal

By João L. Carapinha

Serplulimab lung cancer treatment has received a positive funding recommendation from Portuguese authorities for first-line use in extensive-stage small cell lung cancer (ES-SCLC), despite not demonstrating added therapeutic value over the current standard. No Added Therapeutic Value...